1. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer
- Author
-
Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B. Garon, Giorgio V. Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J.M. Groen, John V. Heymach, Sumithra J. Mandrekar, Isamu Okamoto, Joel W. Neal, Rebecca S. Heist, David Planchard, Jean-Pierre Pignon, Benjamin Besse, B. Besse, B. Lacas, J.P. Pignon, J. Remon, T. Berghmans, S. Dahlberg, E. Felip, Thierry Berghmans, Suzanne Dahlberg, Enriqueta Felip, Edward Garon, Alex A. Adjei, and Rebecca Heist
- Subjects
Cancer Research ,Second line ,Lung Neoplasms ,Carcinoma ,Angiogenesis Inhibitors ,Randomised clinical trials ,Antiaangiogenics ,Individual patient data ,Meta-analysis ,Metastatic ,Non-small cell lung cancer ,Systematic review ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Progression-Free Survival ,Carcinoma, Non-Small-Cell Lung ,Oncology ,Non-Small-Cell Lung - Abstract
BACKGROUND: Now that immunotherapy plus chemotherapy (CT) is one standard option in first-line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need to assess the efficacy of second-line treatments (2LT) with antiangiogenics (AA). We performed an individual patient data meta-analysis to validate the efficacy of these combinations as 2LT. METHODS: Randomised trials of AA plus standard 2LT compared to 2LT alone that ended accrual before 2015 were eligible. Fixed-effect models were used to compute pooled hazard ratios (HRs) for overall survival (OS, main end-point), progression-free survival (PFS) and subgroup analyses. RESULTS: Sixteen trials were available (8,629 patients, 64% adenocarcinoma). AA significantly prolonged OS (HR = 0.93 [95% confidence interval {CI}: 0.89; 0.98], p = 0.005) and PFS (0.80 [0.77; 0.84], p < 0.0001) compared with 2LT alone. Absolute 1-year OS and PFS benefit for AA were +1.8% [-0.4; +4.0] and +3.5% [+1.9; +5.1], respectively. The OS benefit of AA was higher in younger patients (HR = 0.87 [95% CI: 0.76; 1.00], 0.89 [0.81; 0.97], 0.94 [0.87; 1.02] and 1,04 [0.93; 1.17] for patients
- Published
- 2022